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Abstract
The human being is the only mammal capable of walking and simultaneously 
maintaining an upright position. This fact, implies somewhat unfavorable repercus-
sions for the pelvic region that must support the weight of the abdominal organs. A 
prime example of the aforementioned adverse effects of the standing position are 
pelvic organ prolapses (POP). POP surgery is an increasingly important therapeutic 
aspect in clinical practice due to the aging of our population, and is increasingly preva-
lent as a therapeutic option. Surgical techniques can be performed using an abdominal 
or vaginal approach, depending on the medical history, physical examination, and 
experience of the surgeon. Laparoscopic sacrocolpopexy is an adequate therapeutic 
option with a high success rate in 80–100% of cases. However, this technique is not 
always appropriate, especially for patients who are at high risk for anesthesia, a multi-
operated abdomen, or in recurrent prolapse. In these cases, a vaginal approach offers 
an interesting surgical alternative. In this review, we added our experience with trans-
vaginal single-incision mesh under locoregional anesthesia for correction of female 
POP. We retrospectively analyzed 78 patients showing a success rate of 92% after more 
than 12 months of follow up. Transvaginal mesh was developed to maintain the advan-
tage of a vaginal procedure, while reducing the risk of recurrent prolapse compared to 
native tissue repair and simplifying the surgery compared to sacrocolpopexy.
Keywords: Pelvic Organ Prolapse, Reconstructive Surgical Procedures,  
Gynecologic Surgical Procedures
1. Introduction
The human being is the only mammal capable of walking and simultaneously main-
taining an upright position. This fact, greatly affected by the law of gravity, implies 
somewhat unfavorable repercussions for the pelvic region that must support the weight 
of the abdominal organs. Therefore, throughout evolution, fundamental modifications 
have emerged in the pelvic skeleton, and in the surrounding muscles and ligaments, to 
offset the negative effect of the law of gravity. A prime example of the aforementioned 
adverse effects of the standing position are pelvic organ prolapses (POP).
The prevalence of this pathology is clearly on the rise: it is estimated that the  
number of women with pelvic organ prolapse will rise from 3.3 million women in 2010 
to 4.9 million in 2050. Pelvic floor dysfunction is considered to be underdiagnosed, 
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affecting 50% of women, although only 10–20% will seek assistance [1]. More than 
60% of the patients affected by this condition present more than one pathology as the 
pelvic floor organs constitute a functional and organic unit [2]. It is estimated that a 
woman’s risk of undergoing surgery related with POP during her life varies from 6.3 
to 19%, with 30% requiring one or more surgical interventions due to recurrence [3]. 
Some authors have reported re-intervention rates for recurrence after primary recon-
structive surgery of between 43 and 58% [4].
The anatomical support of the pelvic viscera is provided mainly by the levator 
ani and the connective tissue junctions of the pelvic organs: vaginal support arises 
from the connective tissue junctions between the vagina and the pelvic lateral wall, 
the vaginal wall and levator ani muscles [5].
In 1994, Delancey had already introduced the concept of the division of the 
support of the pelvic connective tissue in three levels (I-III) that represent apical, 
mid-vaginal and distal support, respectively. The upper portion of the paracolpium 
(Level I) consists of a lamina from which the vagina is suspended attaching it to the 
pelvic wall, and is responsible for suspending the apex of the vagina after hysterec-
tomy. In the middle third of the vagina, the paracolpium joins the vagina laterally to 
the tendinous arch and the fascia of the elevator ani muscles (Level II). This stretches 
the vagina transversally between the bladder and the rectum. The structural layer 
that supports the bladder (pubocervical fascia) is made up of the anterior vaginal 
region and its attachment through the endopelvic fascia to the pelvic wall. Similarly, 
the posterior vaginal wall and endopelvic fascia (rectovaginal fascia) form the 
containing layer that prevents protrusion of the rectum toward its anterior surface. 
The lower third of the vagina (Level III) fuses with the perineal membrane, levator 
ani muscle, and the perineal body. Defects in the mid-level vaginal base (pubocervi-
cal and rectovaginal fascia) result in cystocele and rectocele, while the loss of upper 
suspensory fibers of the paracolpium and parametrium are responsible for the devel-
opment of vaginal and uterine prolapse, and these defects of combined form [6].
During examination, the prolapse of the anterior compartment is the most 
frequently reported site of prolapse and it is diagnosed twice as frequently as the 
defects of the posterior compartment, and three times more common than apical 
prolapse [7]. After hysterectomy, 6–12% of women will develop a prolapse of the 
vaginal vault [8] and in two thirds, multi-compartmental prolapse will be present.
The etiology of POP is believed to be multi-factorial with contributions from 
both environmental and genetic risk factors. The environmental factors that 
contribute to POP include vaginal delivery and newborn weight, chronic increases 
in intra-abdominal pressure, obesity, advanced age and estrogen deficiency [9].
Not all prolapses are clinically symptomatic, and finding mild asymptomatic 
prolapses during pelvic floor examination is common. If symptoms are present, the 
most frequent complaints include a sensation of pressure, a lump or protrusion and 
with evidence upon physical examination of a second degree or greater anterior  
and / or posterior and / or central vaginal wall prolapse. Ellerkmann et al. found 
that in 237 women evaluated for POP, 73% reported urinary incontinence, 86% 
urinary urgency and / or frequency, 34–62% voiding dysfunction and 31% fecal 
incontinence [10]. Evaluation of a patient with vaginal prolapse requires a compre-
hensive review of the full spectrum of pelvic floor symptoms and an assessment of 
how these symptoms affect her quality of life.
2. Surgical treatment of pelvic organ prolapse
POP surgery is an increasingly important therapeutic aspect in clinical practice 
due to the aging of our population, and is increasingly prevalent as a therapeutic 
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option, despite surgical and hospitalization times that are three times longer 
compared to other surgeries related to the pelvic floor such as continence surgery. 
Given the increasing time and resources that will be required for POP surgery in the 
future, it is paramount that we perform effective, long-lasting and cost-effective 
interventions with minimal morbidity.
Historically, most studies evaluating the treatment of POP have focused 
exclusively on anatomic success without considering other important aspects such 
as symptoms, vaginal accommodation, and quality of life. In fact, for a patient, 
individually, the most important result of a surgical procedure is the relief of their 
symptoms and improvement of their quality of life [11] However, until recently 
these areas have been ignored. The objectives of pelvic floor reconstruction are to 
relieve symptoms, restore anatomy, improve or preserve function, prevent actions 
that alter other compartments, and improve quality of life [12].
Anterior colporrhaphy was the standard procedure in the management of the 
prolapsed anterior compartment. That said in the early 2000s, there was a move-
ment toward the use of prosthetics to increase the efficacy of native tissue repair in 
reconstructive gynecology. This was due to the articles published by Olsen et al. [13] 
where they reported a reoperation rate of 29% after prolapse or continence surgery 
and Weber et al. [14] who reported a 70% failure rate of native tissue anterior 
compartment repair. Recent reassessment of the same demographic 10 years later 
revealed a significantly lower reoperation rate of 17% [15]. More importantly, 
Weber et al. [14] and Sand et al. [16] reported in randomized controlled clinical tri-
als that anterior colporrhaphy was successful in managing cystocele in only 30%. A 
recent re-analysis of the latter data, using the hymen as the threshold for objective 
success, reported considerably better results, with only 10% anatomic recurrence 
beyond the hymen, 5% symptomatic recurrence, and a lower reoperation rate of 1% 
at 23 months of follow-up [17]. During the decade between these initial and later 
publications, surgeons introduced a large number of biologic and mesh grafts to 
improve the outcomes of prolapse surgery. In later studies such as that of Julian et al. 
[18] it was shown that patients with several vaginal repairs had better results with a 
new repair with prosthetic material, in this case a Marlex® mesh (Bard, Covington, 
GA), compared to previous colporrhaphy, although follow-up reported an erosion 
rate of up to 25%.
The 2016 Cochrane Review also reported on 16 trials that evaluated nearly 
2,000 women with the aim of comparing anterior colporrhaphy versus permanent 
polypropylene mesh POP repair. The meta-analysis showed that recurrence of 
anterior wall prolapse (RR 0.34, 95% CI 0.25 to 0.46) and reoperation for prolapse 
(RR 0.44, 95% CI 0.24 to 0.46) were significantly less common after mesh repair 
compared to colporrhaphy. There were no differences between the groups in terms 
of quality of life outcomes or dyspareunia rates. However, the transvaginal poly-
propylene mesh group had higher rates of reoperation due to mesh exposure, stress 
urinary incontinence or prolapse (RR 1.62, 95% CI 1.15 to 2.28), and prolapse in 
the apical or posterior compartment (RR 1.85, 95% CI 1.01 to 3.37) compared to 
anterior colporrhaphy. Surgical time (MD 17.9 min, 95% CI 10.0 to 25.8), transfu-
sion rate (RR 2.37, 95% CI 1.32 to 4.24), cystotomy (RR 4.65, 95% CI 1.22 to 17.77) 
and de novo stress urinary incontinence (RR 1.55, 95% CI 1.02 to 2.35) were higher 
after use of transvaginal polypropylene mesh compared to colporrhaphy. The mesh 
erosion rate was 11.5% and 7% underwent surgical correction for repair [19].
One fact that we must take into account is that recently, most of the products 
made with polypropylene meshes evaluated in this meta-analysis have been with-
drawn by the manufacturers due to the ongoing litigation regarding the use of 
this type of material vaginally. Because of this, new transvaginal polypropylene 
prosthetic products have emerged that have been introduced to decrease the rate 
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of complications, specifically mesh erosion. Altman et al. [20] based on a multi-
center prospective case series, which evaluated 207 women with apical prolapse 
undergoing the Uphold® pelvic floor system (Boston Scientific, USA), reported a 
subjective success rate of 90% per year and a reoperation rate for mesh exposure 
of 1.3%. Similarly, De Tayrac et al. [21] found at 3 years, in 79 women with grade 
3–4 cystocele, an anatomical success rate of 95%, a satisfaction rate of 98% and a 
mesh exposure rate of 1.3% using a mesh of lightweight (28 g / m2) polypropylene 
(Surgimesh® Prolapse Xlight, Aspide Medical, France) [21].
Studies where the device used was Restorelle® (Coloplast, Minneapolis, USA), 
report rates of absence of postoperative complications of 98.2%. The most frequent 
complications included urinary retention (8.7%), urinary tract infections (5.5%), 
and hematoma (2.7%). Other complications related to neighboring organs (bladder, 
rectum, and ureters) were very rare (<1%). A total of 2.8% of the patients had grade 
III complications according to the Clavien-Dindo classification (mesh extrusion). 
80.3% did not present complications during the 3 months of study follow-up. 
Despite these promising data, the follow-up time of this study is short to ensure the 
absence of complications within a longer follow-up period [22]. Despite the current 
negative sentiment around transvaginal mesh, these new lightweight mesh products 
require further reassessment.
In the 2016 Cochrane meta-analysis of grafts vs. Native tissue repairs for vaginal 
prolapse, only one case of reoperation for dyspareunia or pain was reported in the 
nearly 1000 cases of transvaginal mesh evaluated [19]. However, pain and dyspa-
reunia were the main causes of adverse events that triggered the 2011 FDA (Food 
and Drug Administration) warnings on the safety of transvaginal mesh [23]. These 
findings raise the possibility that pain and dyspareunia after transvaginal mesh 
surgery may be underreported, and possibly only identified in trials with longer 
term evaluation.
Alternatively, autologous material was considered as a possible option to syn-
thetic prosthetic grafts with a lower risk of host rejection or infection. Gandhi et 
al. reported preliminary results of a randomized control trial comparing anterior 
colporrhaphy alone vs. fascia lata graft for cystoceles [24]. In 1 year they could not 
demonstrate that the addition of the fascia lata graft improved the success rate 
compared to anterior colporrhaphy alone, being 71% compared to 82% (p 0.07), 
however, the rate of recurrent anterior prolapse in examination was lower after 
biological graft repair compared to anterior colporrhaphy (RR 0.74, 95% CI 0.55 
to 0.99 n = 646, I2 = 29%, low-quality evidence), being the operative time for 
colporrhaphy shorter than the biological graft procedure (MD -10.35, 95% CI -14.45 
to −6.24).
Reoperation after POP surgery for recurrence is an important measure of the 
effectiveness of the procedure. It is important to note that reoperation rates represent 
the “tip of the iceberg” in terms of surgical failures, as there are women with recur-
rent symptomatic prolapse who do not wish to undergo another operation. However, 
repeat surgery for recurrent POP is always an undesirable result that should, in most 
cases, be considered as a failed surgical procedure. Reoperation rates after POP sur-
gery vary widely in the literature, largely due to different definitions and timelines. 
In a meta-analysis of 258 studies evaluating the reoperation rate after apical prolapse 
repairs, Diwadkar et al. reported a reoperation rate of 3.9% (95% CI: 3.5–4.4%) for 
traditional vaginal vault suspensions (sacrospinal ligament suspension and utero-
sacral vault suspensions) after a mean of 32 months, 2.3% (95% CI 1.9–2.7%) for 
sacrocolpopexy with follow-up mean 26 months and 1.3% (95% CI 1.0–1.7%) after 
transvaginal mesh procedures with a mean follow-up of 17 months. In particular, the 
total reoperation rate, including reoperations for recurrent POP and complications, 
was higher in the transvaginal mesh group (8.5%) [25].
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The reoperation rate after POP surgery was defined in the joint report by the ICS 
(International Continence Society) and the IUGA (International Urogynecological 
Association), making a clear distinction between additional surgeries after primary 
surgical correction of POP, as the character of these can be very heterogeneous. The 
classification of these surgeries was established as follows:
• Primary prolapse / different compartment surgery - prolapse in a new  
compartment after previous surgery in a different compartment.
• Repeat surgery - is a repeat operation for prolapse that arises from the  
compartment that was previously operated on.
• Surgery for complications (e.g. exposure or extrusion of the mesh, pain, or 
hemodynamic compromise of the patient, hemorrhage).
• Surgery for conditions not related to prolapse (e.g. subsequent surgery for 
stress urinary incontinence or fecal incontinence).
Recently, Ow et al. retrospectively compared 237 women who underwent 185 
native tissue repairs and 161 transvaginal mesh repairs for recurrent prolapse. The 
transvaginal mesh group had significantly lower follow-up rates of symptomatic 
prolapse, prolapse upon examination, and reoperation for prolapse, than the native 
tissue repairs group. However, the mesh exposure rate (anterior 15%, posterior 
mesh 21%) and associated reoperation (anterior 9%, posterior 15%) were sig-
nificantly higher [26]. Trials such as this one show that in women with recurrent 
prolapse, transvaginal mesh has significant advantages and disadvantages com-
pared to native tissue repairs and this profile is similar to that described for primary 
repairs, except that the exposure rates of the mesh appear to be higher in recurrent 
POP surgery.
Another surgical alternative on the rise in the last decade is laparoscopic or 
robotic sacrocolpopexy. This was born with the purpose of maintaining the existing 
good results of abdominal sacrocolpopexy but with the advantages of minimally 
invasive surgery. The case series demonstrate adequate acceptance in the short 
and medium term, with success rates of 91% (range 60–100%), subjective success 
rates of 79–98% [27, 28] and a mean reoperation rate of 5.6%. In a meta-analysis, it 
was concluded that, in general, a large group of vaginal surgery with and without 
mesh is associated with a higher risk of prolapse recurrence upon examination 
(RR 1.9 95% CI 1.3–2.7), of reoperation for prolapse recurrence (RR 2.3 95% CI 
1.2–4.3), postoperative stress urinary incontinence (RR 1.9 95% CI 1.2–2.9) and 
dyspareunia (RR 2.5 95% 1.2–5.5) compared with sacrocolpopexy [29]. However, 
sacrocolpopexy was associated with a higher rate of paralytic ileus or small bowel 
obstruction (2.7% vs. 0.2%, p < 0.01), of complications related to intraperitoneal 
mesh or suture (4.2% vs. 0.4%, p < 0.01) and thromboembolic disease (0.6% vs. 
0.1%, p = .03) [30].
The robotic sacrocolpopexy is the currently latest version of this technique. The 
robotic approach is associated with objective cure rates of 84% -100%, subjective 
cure rates of 92–95%, and a mesh erosion rate of 2% (range 0–8%). In general, 
we can find postoperative complications in this meta-analysis in up to 11% (range 
0–43%), with serious complications in 2%, with a conversion rate of <1% to open 
surgery (range 0–5%) [31].
Traditionally, researchers have defined surgical success using anatomical results 
(POP-Q stage 0–1 - Table 1) and defined surgical failure as POPQ stage 2 or greater. 
More recently it is suggested that these anatomical definitions are too strict as more 
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than 75% of women presenting for annual gynecological exams with no symptoms 
of pelvic organ prolapse would not be found in the definition of “optimal anatomical 
result” and almost 40% would not meet the definition of “satisfactory anatomical 
result” [32]. The absence of symptoms of vaginal protrusion postoperatively has a 
significant relationship with the patient’s evaluation of general improvement and 
improvement in quality of life after surgery, while anatomical success alone does not, 
and thus vaginal protrusion symptoms are of great importance when evaluating the 
surgical outcome of POP [11]. Another possible factor to take into account in the dif-
ferent studies is the concept of success used together with the POP classification used. 
Some authors have used the Baden-Walker prolapse classification system instead of 
the POP-Q, other studies have used a combination of anatomical criteria and the pres-
ence or absence of symptoms to define the success of the treatment. Such variability 
makes it difficult to compare the results between the different studies.
3. Case study
3.1 Aim and scope
In this study we will show the results obtained at our center with one of the most 
recent devices for the transvaginal correction of female POP, the Restorelle® single-
incision mesh (Coloplast, USA). This product was later withdrawn from the market 
along with other transvaginal prosthetic devices for the correction of POP (April 
2019), following its ban by the FDA.
Restorelle® Direct Fix Mesh products incorporate Smartmesh® technology 
(physiologically compatible ultralight mesh). It provides long-term strength while 
maintaining the vaginal elasticity of natural tissue. Its placement allows for an 
anterior sacrospinous ligament approach, using a disposable device (Digitex®) 
designed to place sutures without direct visualization. The proximal arms of the 
mesh are sutured to the anterior sacrospinous ligament and the distal arms of the 
mesh are sutured to the arch of the pelvic tendinous fascia.
3.2 Study design and material and methods
Retrospective study of patients who underwent surgical correction of POP in 
the same center between January 2016 and December 2017 with the Restorelle® 
Pelvic organ prolapse quantification system (POP-Q )
Stage Description
0 No prolapse, anterior and posterior points are all −3 cm, and C or D is between -TVL and -(TVL-2) 
cm
1 The criteria for stage 0 are not met, and the most distal prolapse is more than 1 cm above the level 
of the hymen (less than −1 cm)
2 The most distal prolapse if between 1 cm above and 1 cm below the hymen (at least one point is −1. 
0, or + 1)
3 The most distal prolapse is more than 1 cm below the hymen but no further than 2 cm less than TVL
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device. We analyzed demographic variables, prolapse characteristics, associated 
symptoms, gynecological history, recurrence, and degree of satisfaction taken from 
the existing medical history. The degree of POP was evaluated according to the 
Baden-Walker classification. The surgical indication was symptomatic patients with 
grade ≥ 2 POP (primary or recurrent). All interventions were performed by a single 
surgeon after an antibiotic prophylaxis protocol.
3.3 Results of the study
We retrospectively analyzed 78 patients operated on at our center with a mean 
age of 64.2 years (48–78). The comorbidities evaluated were diabetes mellitus (DM) 
(21%), arterial hypertension (48%), with a body mass index (BMI) of 27.5 kg/m2 and 
a mean parity of 2.2 births (1–5). 36% of our patients had a history of gynecologi-
cal surgical, the most prevalent being hysterectomy in up to 50% of the operated 
patients. The most frequently treated prolapse was anterior (72%), followed by pos-
terior (12%) and mixed anterior–posterior (12%), with only one case of apical and 
posterior prolapse. Of these, 4 were recurrent prolapses. The most common grade of 
prolapse was III and IV with a frequency of 54% and 42%, respectively (Table 2).
Regarding the functional and clinical results, 50% of the sexually active patients 
had preoperative dyspareunia, which persisted after the intervention in two 
Demographics Variable value (n = 78)
Age (years) 64.2 (48–78)
BMI (kg/m2) 27.5 (21.9–33.3)
<25 13 (16.7%)
25–29.9 46 (59%)
>30 27 19 (24.4%)
DM 17 (21.8%)
Arterial hypertension 38 (48.7%)
Clinical history
Parity 2.2 (1–5)
Previus gynecological operation 28 (36%)
Previous hysterectomy 14 (18%)







Stage 2 2 (2.6%)
Stage 3 43 (55.1%)
Stage 4 33 (42.3%)
Values are presented as median [range] or number (%); BMI: body mass index; POP: pelvic organ prolapse.
Table 2. 
Demographic variables and clinical characteristics before surgery.
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patients. Preoperative UI (urinary incontinence) was present in 48%, with urgency, 
stress UI and mixed UI in 37%, 31% and 19% respectively. 18% of these patients 
resolved their UI and 12% had postoperative UI (Table 3). We obtained a success 
rate of 92%, understood as absence of extrusion (6%), pain (3%) or functional 
recurrence (3%) 6 months after surgery. The anatomic recurrence rate was 9%. 
The total Clavien-Dindo IIIa complication rate was the most prevalent with 6.4% 
(extrusion), followed by grade II (3.8%). There were none in group IV or V. Cases 
of extrusion were resolved on an outpatient basis with local anesthesia. The mean 
follow-up time was 13.5 months. In general, the patients were satisfied (57.7%) or 
very satisfied (36%), and only 6.4% of the patients were dissatisfied and none were 
very dissatisfied.
4. Discussion
Surgical techniques can be performed using an abdominal or vaginal approach, 
depending on the medical history, physical examination, and experience of the 
surgeon. Laparoscopic sacrocolpopexy is an adequate therapeutic option with a high 
success rate in 80–100% of cases [33, 34]. However, this technique is not always 
appropriate, especially for patients who are at high risk for anesthesia, a multi-oper-
ated abdomen, or in recurrent prolapse. In these cases, a vaginal approach offers 
an interesting surgical alternative. Transvaginal mesh was developed to maintain 
the advantage of a vaginal procedure, while reducing the risk of recurrent prolapse 
compared to native tissue repair.
In the short and medium term, our results are similar to the articles published 
in relation to the success rate of studies with the same device and implantation 
route (92% in our series vs. 80.3%) [22] and different prosthetic devices but with 
the same implantation route (91.3%) [35], although its comparison is difficult due 
to the existence of different follow-up times. In our series, the minimum follow-up 
time was 6 months, while in studies such as the one published by Ferry et al. [22] 
they only had 3 months of follow-up. We could say that our success rate is slightly 
higher, despite a longer follow-up. Our good results may be due to the fact that all 
surgeries were performed by a single surgeon with extensive experience in vaginal 
Results Preoperative Postoperative
Dyspareunia 21 (26.9%) 2 (2.6%)
Urinary incontinence: 38 (48%) 24 (30.7%)
Urgency 29 (37.2%) 27 (34.6%)
Stress 24 (30.8%) 12 (15.4%)
Mixed 15 (19.2%) 8 (10.3%)




Functional recurrence 3 (3,8%)
Anatomical recurrence 7 (9%)
Table 3. 
Results and complications during follow-up.
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POP correction surgery with mesh interposition. If we compare other techniques 
with a recent boom, such as laparoscopic or robotic sacrocolpopexy [27, 28], there 
are also no great differences with respect to the success rate, 92% in our series versus 
80–100% in those mentioned.
Our anatomical correction rate at 6 months of follow-up was 91%, similar to 
that found in other studies with this same device, 87.9% [22] or other light weight 
devices with the same implantation route, which oscillates between 79 and 96.5% 
[35–37], although their comparison is equally difficult due to different follow-up 
times. This same mesh surgery with the same anatomical correction rate criterion 
was 98.7% at 36 months for De Tayrac et al. [21] and 93.7% for Denance´ et al. 
[38]. Most of the published studies are retrospective [39], and those that are pro-
spective have a follow-up period that is too short. If we compare other techniques 
such as robotic sacrocolpopexy [27], we find similar rates of absence of anatomic 
recurrence (95%).
Regarding the complications observed, the mesh extrusion rate in our series was 
6.4% compared to 1.3–11.5% published in other studies with lightweight vaginal 
mesh (28 g / m2) [19, 21]. In a study published with the Restorelle® device, an 
extrusion rate of 2.8% was observed, lower than that obtained at our center. Again, 
this difference can be justified because the postsurgical follow-up at our center was 
more than double that of the referenced study [22]. Furthermore, in general, we 
can affirm that it is difficult to compare our data with the literature, as there is great 
diversity of previously available prosthetic products.
The functional results obtained are similar to those published to date. We can find 
postoperative dyspareunia in 1.76% of patients in some existing studies after the use 
of transvaginal mesh [36, 40], a rate very similar to that of our study with only two 
existing cases. In the case of laparoscopic sacrocolpopexy, there seems to be a lower 
risk of dyspareunia compared to the transvaginal implantation device (RR 0.39, 
95% CI 0.18) [41, 42]. Incontinence rates were lower after correction of the pro-
lapse, mainly, stress urinary incontinence improved [40, 43]. and 12% of new cases 
appeared. On the other hand, the appearance of de novo stress urinary incontinence 
is common in the treatment of prolapse with the use of prosthetic material (RR 1.55, 
95% CI 1.02 to 2.35 - anterior colporrhaphy versus use of transvaginal mesh), a fact 
that patients undergoing this surgery should always be advised of. However, our rate 
of de novo urinary incontinence with the use of transvaginal mesh is similar to that 
published with the laparoscopic colposacropexy technique (12%) [41].
Summarizing, we can state that transvaginal single incision-mesh have several 
advantages compared to classical approaches like colposacropexy or other mesh 
devices. It avoids the peritoneal cavity, truly important in patients with previous 
abdominal surgeries, reducing the risk of paralytic ileus and making possible a 
shorten recovery. As we have shown in our cases study, it can be done under locore-
gional anesthesia, allowing to perform this surgery almost without hospital stay. 
And finally, the esthetic results are obviously better, as we can avoid any abdominal 
scar, a fact that is especially transcendent in young women.
Our study presents several limitations. The first of these is the retrospective 
and non-randomized nature of our study. Furthermore, all the interventions were 
carried out by the same surgeon with great experience, which makes it difficult to 
reproduce these results in other centers and makes it difficult to compare them with 
other studies. On the other hand, the results of the treatments of non-oncological 
pathologies usually respond to very high expectations on behalf of the patients, so 
we can consider a limitation of our study the absence of quality of life question-
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5. Conclusion
In our experience, the Restorelle® device and its transvaginal placement is a 
safe procedure, with low morbidity and a high satisfaction rate in properly selected 
patients and in the hands of expert surgeons. Complications are rare and can be 
resolved by outpatient surgery.
Considering long-term complications is essential to properly weigh the risk–
benefit ratio of each procedure, which is why more studies with a longer follow-up 
period than those currently available in the literature are necessary to judge this 
type of device with more evidence.
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Appendices and nomenclature
BMI  Body mass index
DM  Diabetes mellitus
FDA  Food and Drug Administration
ICS  International Continence Society
IUGA International Urogynecological Association
POP  pelvic organ prolapses
UI  urinary incontinence
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